These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 5655824)

  • 1. Analysis of change in ultracentrifugal lipoprotein profiles following heparin and ethyl-p-chlorophenoxyisobutyrate administration.
    Nichols AV; Strisower EH; Lindgren FT; Adamson GL; Coggiola EL
    Clin Chim Acta; 1968 May; 20(2):277-83. PubMed ID: 5655824
    [No Abstract]   [Full Text] [Related]  

  • 2. THE EFFECT OF SF 20-10-5 CONCENTRATION CHANGES INDUCED BY ETHYL CHLOROPHENOXYISOBUTYRATE ON HIGH-DENSITY LIPOPROTEIN LIPID COMPOSITION.
    STRISOWER EH; NICHOLS AV; LINDGREN FT; SMITH L
    J Lab Clin Med; 1965 May; 65():748-55. PubMed ID: 14281371
    [No Abstract]   [Full Text] [Related]  

  • 3. [Action of ethyl chlorophenoxyisobutyrate on several types of hyperlipidemia].
    Beaumont V; Swynghedauw B; Beaumont JL; Himbert J
    Rev Atheroscler (Paris); 1966; 8(1):12-20. PubMed ID: 5961026
    [No Abstract]   [Full Text] [Related]  

  • 4. [Association of neomycin sulfate and ethyl-p-chlorophenoxybutyrate in the treatment of dyslipemia].
    Bertulla A; Bertamino V; Solari E
    Ateneo Parmense 1; 1971; 42(2):103-14. PubMed ID: 5154400
    [No Abstract]   [Full Text] [Related]  

  • 5. [Experience with 110 medium-length therapeutic trials of ethyl chlorophenoxyisobutyrate with or without androsterone in various types of idiopathic hyperlipidemia].
    De Gennes JL; Maunand B; Salmon D; Laudat P; Truffert J
    Rev Atheroscler (Paris); 1966; 8(1):27-52. PubMed ID: 5961027
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of Al-chlorophenoxyisobutyrate (Alufibrate) on pyruvate metabolism and on the fate of very low density lipoprotein lipids in hyperlipidemic patients.
    Stähelin HB; Locher JT; Maier R
    Clin Chim Acta; 1974 Jul; 54(1):115-22. PubMed ID: 4367872
    [No Abstract]   [Full Text] [Related]  

  • 7. Ultracentrifugal demonstration of floating beta lipoproteins in type 3 hyperlipoproteinemia. Diagnostic value.
    Aubry F; Lapierre YL; Noël C; Davignon J
    Ann Intern Med; 1971 Aug; 75(2):231-7. PubMed ID: 5558651
    [No Abstract]   [Full Text] [Related]  

  • 8. [Long-term treatment of previously therapy-resistant cases of primary hypertriglyceridemia of the adult with ethyl-p-chlorophenoxyisobutyrate].
    Braunsteiner H; Herbst M; Sandhofer F; Sailer S
    Dtsch Med Wochenschr; 1967 Dec; 92(50):2302-8. PubMed ID: 6075896
    [No Abstract]   [Full Text] [Related]  

  • 9. [Determination of pre-beta-lipoprotein and its clinical significance].
    Naito C
    Naika; 1969 Jul; 24(1):36-42. PubMed ID: 4896508
    [No Abstract]   [Full Text] [Related]  

  • 10. [Action of aluminum bis-parachlorophenoxyisobutyrate (2CPIBA) on various hyperlipoproteinemias: initial results].
    Vastesaeger MM; Peeters H; Blaton V; Vanderveiken F; Vastesaeger E
    Brux Med; 1969 Oct; 49(10):615-29. PubMed ID: 5402903
    [No Abstract]   [Full Text] [Related]  

  • 11. [Clinical-experimental studies on lipid metabolism using Regelan].
    Hammerl H
    Wien Klin Wochenschr; 1967 Sep; 79(39):720-2. PubMed ID: 4875575
    [No Abstract]   [Full Text] [Related]  

  • 12. Very low density lipoprotein subfractions in a subject with broad-beta disease (Type 3 hyperlipoproteinemia) and a subject with endogenous lipemia (Type IV). Chemical composition and electrophoretic mobility.
    Hazzard WR; Lindgren FT; Bierman EL
    Biochim Biophys Acta; 1970 May; 202(3):517-25. PubMed ID: 5442187
    [No Abstract]   [Full Text] [Related]  

  • 13. Measurements of the molecular weight variability of plasma low density lipoproteins among normals and subjects with hyper- -lipoproteinemia. Demonstration of macromolecular heterogeneity.
    Fisher WR; Hammond MG; Warmke GL
    Biochemistry; 1972 Feb; 11(4):519-25. PubMed ID: 4334903
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term therapy of adult cases of primary hypertriglyceridaemia with clofibrate (ethyl-p-chlorophenoxyisobutyrate).
    Braunsteiner H; Herbst M; Sandhofer F; Sailer S
    Ger Med Mon; 1968 Feb; 13(2):65-72. PubMed ID: 5653144
    [No Abstract]   [Full Text] [Related]  

  • 15. Flotation rates, molecular weights and hydrated densities of the low-density lipoproteins.
    Lindgren FT; Jensen LC; Wills RD; Freeman NK
    Lipids; 1969 Sep; 4(5):337-44. PubMed ID: 5823713
    [No Abstract]   [Full Text] [Related]  

  • 16. On the metabolic conversion of human plasma very low density lipoprotein to low density lipoprotein.
    Eisenberg S; Bilheimer DW; Levy RI; Lindgren FT
    Biochim Biophys Acta; 1973 Dec; 326(3):361-77. PubMed ID: 4359865
    [No Abstract]   [Full Text] [Related]  

  • 17. [The effect of ethyl-chlorophenoxyisobutyrate on the serum lipids in coronary sclerosis].
    Keller L; Rétsági G; Sebestyén M; Diczendy S; Erdélyi G
    Z Gesamte Inn Med; 1966 Mar; 21(6):169-72. PubMed ID: 5988081
    [No Abstract]   [Full Text] [Related]  

  • 18. Heterogeneity on familial hyperlipoproteinemia type II on the basis of fasting plasma triglyceride-cholesterol ratio and plasma cholesterol response to ethyl p-chlorophenoxyisobutyrate.
    Davignon J; Aubry F; Noël C; Lapierre Y; Lafortune M
    Rev Can Biol; 1971 Dec; 30(4):307-18. PubMed ID: 5135408
    [No Abstract]   [Full Text] [Related]  

  • 19. [Hyperlipidemias: occurrence, significance, therapy].
    Knüchel F
    Med Welt; 1967 Aug; 32():1848-60. PubMed ID: 5589916
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of hyperlipidemia with the ethyl-ester of chlorophenoxyisobutyrate and androsterone.
    Schatz IJ
    Henry Ford Hosp Med J; 1965 Dec; 13(4):447-56. PubMed ID: 5325188
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.